Regulus Therapeutics
RGLS
$1.30
Share price
-2.26%
Change (1 day)
-53.57%
Change (1 year)
Categories
Operating Margin for Regulus Therapeutics (RGLS)
Operating Margin as of June 2023 (TTM): -119.48%
According to Regulus Therapeutics's latest financial reports and stock price the company's current Operating Margin is -119.48%. At the end of 2020 the company had an Operating Margin of -157.21%.
Operating Margin history for Regulus Therapeutics from 2012 to 2020
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2020 | -157.21% | -42.23% |
| 2019 | -272.12% | -99.6% |
| 2018 | -67,565.28% | -32.53% |
| 2017 | -100,141.67% | 1361.01% |
| 2016 | -6,854.27% | 2451.52% |
| 2015 | -268.64% | -63.65% |
| 2014 | -739.07% | 673.78% |
| 2013 | -95.51% | -30.36% |
| 2012 | -137.15% | 155.7% |
| 2011 | -53.64% | -70.41% |
| 2010 | -181.25% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | 19.90% | -116.66% | 🇫🇷 France |
 Biogen BIIB | 36.44% | -130.50% | 🇺🇸 USA |
 Bristol-Myers Squibb BMY | 19.18% | -116.05% | 🇺🇸 USA |
 AstraZeneca AZN | -0.70% | -99.41% | 🇬🇧 UK |
 GlaxoSmithKline GSK | 18.87% | -115.79% | 🇬🇧 UK |
 Sangamo Therapeutics
SGMO | -160.78% | 34.57% | 🇺🇸 USA |
 Dicerna Pharmaceuticals DRNA | -61.01% | -48.94% | 🇺🇸 USA |
 Alnylam Pharmaceuticals
ALNY | -100.93% | -15.53% | 🇺🇸 USA |
What is a company's Operating Margin
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.